Granted Patent B2

US 12,459,983 · App. 18/650,881 · Granted Nov 4, 2025

Inventor: Alexander Kamb (Agoura Hills, CA)

Assignee: A2 BIOTHERAPEUTICS, INC.

C07K14/7051A61K35/17A61K40/11A61K40/31A61K40/32A61K40/4204A61K40/4268A61K40/4269C07K14/4702C12N5/0637C12N15/85C07K2317/53C07K2317/622C07K2319/03C07K2319/715C12N2510/00

Abstract

Claims (13)

1 . A method of producing an engineered immune cell, the method comprising:

determining a strength of a blocking signal sent from a cell surface blocking receptor on an engineered immune cell at least in-part due to a length of a hinge of the cell surface blocking receptor, said receptor expressed from one or more engineered polynucleotide in the engineered cell, wherein longer hinge lengths impart an increased blocking signal strengths for the cell surface blocking receptor;

wherein the hinge is of a known length and comprises a peptide derived from leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) of between 10 and 64 amino acids in length; and

introducing the one or more polynucleotide into a cell thereby producing an engineered immune cell that expresses the cell surface blocking receptor and a cell surface activating receptor that sends an activating signal that the promotes a cytotoxic response is inhibited by the blocking signal and the cell surface blocking receptor with a known hinge length.

2 . The method of claim 1 , wherein cross-talk and/or structure function interactions between the hinge of the blocking receptor and the activating receptor further impart different signal strengths for the blocking receptor.

3 . The method of claim 1 , wherein the increased blocking signal strength increases a half maximal effective concentration (EC 50 ) of an activating ligand for the activating receptors, wherein binding of the activating ligand to the activating receptor causes the receptor to send the activating signal to promote the cytotoxic response.

4 . The method of claim 3 , wherein the peptide of the hinge has a degree of flexibility, and the peptide's length and degree of flexibility modulate the blocking signal strength of the blocking receptor on the activating signal.

5 . The method of claim 4 , wherein the hinge is selected from hinges that each have a known effect on the EC50 of the activating ligand for the activating receptors to promote the cytotoxic response.

6 . The method of claim 5 , wherein the peptide of the hinge is at least 24 amino acids in length.

7 . The method of claim 5 , wherein the peptide of the hinge is at least 64 amino acids in length.

8 . The method of claim 7 , wherein a hinge having a peptide of 64 amino acids in length causes at least a fifty-fold increase in the EC50 relative to a hinge having a peptide of 10 amino acid in length.

9 . The method of claim 4 , wherein the flexible peptide comprises glycine-glutamine repeats and/or glycine-serine repeats.

10 . The method of claim 1 , wherein the hinge comprises a rigid peptide that modulates the effect of the blocking signal on the activating signal, and the effect is a reduced inhibition of the activating signal.

Assignments (1)

Continuity (10)

References Cited (70)